Slxn stock forecast from a sector view

From a sector view, SLXN stock forecast indicates alignment with broader NASDAQ tech trends, wherein AI-driven data solutions are gaining traction, potentially enhancing its valuation multiples over the next 6–12 months. SNL returns swinging as Trump sketch rips into wars, late-night feuds and Epstein ties Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN ) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company’s ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282932). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.3 million , prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about January 30, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes. Market volatility in tech has narrowed, and SLXN stock forecast models now highlight a beta of 1.12, implying moderate sensitivity to broader market swings while preserving relative stability.